Christopher Lovell
Family · Mobile, ALNPI 1861808230
Payments from drug & device makers
Across 609 payments — averaging $105.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$28K
- AbbVie$19K
- Madrigal Pharmaceuticals$13K
- Takeda Pharmaceuticals U.S.A., Inc.$651
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$590
- Novo Nordisk$442
- plus $3K from 27 others
What the payments were for
- Consulting fees$1,4952%
- Speaking & faculty fees$40,99064%
- Travel & lodging$8,86714%
- Food & beverage$12,91320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 111 | $28,470 |
| AbbVie | 225 | $18,596 |
| Madrigal Pharmaceuticals | 46 | $12,758 |
| Takeda Pharmaceuticals U.S.A., Inc. | 31 | $651 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 46 | $590 |
| Novo Nordisk | 7 | $442 |
| Johnson & Johnson | 21 | $348 |
| Intercept Pharmaceuticals, Inc. | 14 | $346 |
| Ipsen Biopharmaceuticals, Inc | 11 | $261 |
| Pfizer | 13 | $229 |
| Lilly USA, LLC | 10 | $169 |
| Redhill Biopharma Inc. | 10 | $142 |
| Phathom Pharmaceuticals, Inc. | 10 | $134 |
| AstraZeneca | 1 | $122 |
| Ardelyx, Inc. | 7 | $116 |
| Regeneron Healthcare Solutions, Inc. | 4 | $114 |
| Daiichi Sankyo Inc. | 6 | $113 |
| Sanofi | 4 | $108 |
| Ironwood Pharmaceuticals, Inc | 4 | $71 |
| Evoke Pharma, Inc. | 4 | $69 |
| Bristol Myers Squibb | 4 | $64 |
| Merck | 3 | $57 |
| Janssen Scientific Affairs, LLC | 1 | $49 |
| Ferring Pharmaceuticals Inc. | 3 | $44 |
| Aimmune Therapeutics, Inc. | 2 | $33 |
| Fresenius Kabi USA, LLC | 2 | $32 |
| Amgen | 2 | $31 |
| Celltrion USA Inc. | 2 | $28 |
| Nestle Healthcare Nutrition Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $15 |
| Braintree Laboratories, Inc. | 1 | $15 |
| Exact Sciences | 1 | $14 |
| Organon | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$64,265 in reported general payments places this provider in the 95th percentile of 3,415 family providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpclusaSofosbuvir/Velpatasvir | 27 | $658,543 |
| Sofosbuvir-VelpatasvirSofosbuvir/Velpatasvir | 50 | $425,494 |
| XifaxanRifaximin | 48 | $165,676 |
| VemlidyTenofovir Alafenamide | 36 | $53,887 |
| RezdiffraResmetirom | 12 | $46,808 |
| LinzessLinaclotide | 41 | $32,772 |
| MotegrityPrucalopride Succinate | 11 | $6,021 |
| Dexlansoprazole DrDexlansoprazole | 17 | $3,572 |
| Budesonide DrBudesonide | 12 | $2,263 |
| Mycophenolate Mofetil | 13 | $1,853 |
| SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag | 13 | $1,637 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 19 | $1,326 |
| Ursodiol | 11 | $1,302 |
| Lubiprostone | 11 | $1,180 |
| Lactulose | 20 | $728 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadEpclusa, Vemlidy | $28,470 | $712,43063 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $590 | $165,67648 claims |
| Madrigal PharmaceuticalsRezdiffra | $12,758 | $46,80812 claims |
| AbbVieLinzess | $18,596 | $32,77241 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $651 | $6,02111 claims |
| Braintree Laboratories, Inc.Suflave | $15 | $1,63713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,415 family providers in Alabama.
Other family in Mobile
- Sanjyot BhadkamkarMobile$16K
- Freda SmithMobile$14K
- Alexandria HellmichMobile$13K
- Kara BoutwellMobile$12K
- Justin WilsonCullman$1.1M
- Leigh Ann ChildressHuntsville$240K
- Molly ReevesAuburn$158K
- Christina CanteyHuntsville$118K
- Leigh LunaMontgomery$69K
- Justin SimpsonTuscaloosa$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.